Clinical Trial Update: Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating atezolizumab in recurrent BCG-unresponsive non-muscle invasive bladder cancer has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7 | Phase 2 | Status: COMPLETED | Results posted: 2023-12-15